|Articles|June 26, 2007

NIH Announces Pediatric Seizure Study

The National Institute of Child Health and Human Development (NICHD) has announced plans to conduct a large-scale study to determine which of the two most commonly-prescribed medications; diazepam (Valium) or lorazepam (Ativan), is the safer and more effective treatment for children with status epilepticus [more].

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

FDA approves omidubicel-onlv as first HSCT therapy to treat severe aplastic anemia

ByJoshua Fitch, Senior Editor

December 8th 2025

ASH data: Marstacimab improves bleeding outcomes in adolescents, adults with hemophilia A or B

ByJoshua Fitch, Senior Editor

December 8th 2025

Can you diagnose this slender teen with a growing abdomen and shrinking height velocity?

ByVanessa Victor-Linkenhoker, MD,Jessica Lamie, OMS-IV,Marie Nicole Antonios, OMS-IV

December 8th 2025

Using genome and exome sequencing as early diagnostic tools, according to Christine Eng, MD

ByChristine Eng, MD

December 8th 2025

Repeal of nonmedical exemptions linked to rise in kindergarten vaccination rates

ByMorgan Ebert, Managing Editor

December 6th 2025

Latest CME

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

NIH Announces Pediatric Seizure Study

Newsletter

Related Content

FDA approves omidubicel-onlv as first HSCT therapy to treat severe aplastic anemia

ASH data: Marstacimab improves bleeding outcomes in adolescents, adults with hemophilia A or B

Can you diagnose this slender teen with a growing abdomen and shrinking height velocity?

Using genome and exome sequencing as early diagnostic tools, according to Christine Eng, MD

Repeal of nonmedical exemptions linked to rise in kindergarten vaccination rates

Latest CME

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

ACIP votes to update hepatitis B vaccine recommendation for infants

ASH data: Marstacimab improves bleeding outcomes in adolescents, adults with hemophilia A or B

FDA approves omidubicel-onlv as first HSCT therapy to treat severe aplastic anemia

Using genome and exome sequencing as early diagnostic tools, according to Christine Eng, MD

Hepatitis B Foundation president discusses recommendations for infant vaccination